Once-weekly semaglutide versus placebo in adults with increased fracture risk: a randomised phase 2 trial
Clinical Evidence: Heart Attack and Stroke Risk Reduction The SUSTAIN-6 trial, which followed over 3,000 people with type 2 diabetes and existing heart disease or high cardiovascular risk, found that semaglutide reduced the combined risk of heart attack, stroke, and cardiovascular death by 26% compared to placebo
Higher doses have not been shown either to be safe or to produce better outcomes
Medications like Ozempic, Mounjaro, and Trulicity work by mimicking the GLP-1 hormone, which increases insulin secretion, slows gastric emptying, and reduces appetite. However, these benefits come with a high price tag, prompting some individuals to seek compounded versions. While compounded alternatives may seem like the same medication at a fraction of the cost, they come with significant risks. Brand Name GLP-1 Medications Brand name GLP-1 medications have undergone thorough testing to receive FDA-approval
Limitations This review is subject to several limitations inherent in the included studies as great evidence is derived from animal and in-vitro models of PD
Vendors shipping in standard envelopes without cold chain protection demonstrate fundamental incompetence or indifference